Truth be told, one of the biggest draws to using CBD oil for pain has been the fact that it has little distinguishable side-effects or contraindications with other medications. In fact, in a massive report that was published by the World Health Organization during last year’s 2017 Expert Committee on Drug Dependence, it was (finally) declared to the world that CBD is a “safe, well tolerated [compound, which] is not associated with any significant adverse public health effects.”
“There is a great deal of confusion regarding the legal status of hemp and why these products are so readily available versus marijuana-based CBD products. In 2014, the Farm Bill stated that hemp was different from marijuana, yet the Drug Enforcement Agency’s (DEA) position is that hemp comes from the cannabis sativa plant and as such falls under the controlled substance act. In 2004, the Hemp Industry Association won a court case against the DEA from the Ninth Circuit Court of Appeals that ruled the DEA didn’t have the authority to ban hemp under the CSA. “By that federal court ruling, similar to non-scheduled hemp food products, this allows Medical Marijuana, Inc. (including HempMeds®) to sell online and distribute to customers in the U.S. states,” said Dr. Stuart Titus, the company’s Chief Executive Officer.”
When California passed Prop. 64, there was a provision that allowed for the production of industrial hemp. Now, that little provision could generate quick growth (pun intended, naturally) for its many applications in the Golden State.It led the forefront for THC now it could be the American leader for hemp CBD. California led the cannabis reform and now will be one of the leaders in an ever expanding cannabis ecosystem.
Your product is not generally recognized as safe and effective for the referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in section 505(a) of the Act [21 U.S.C. § 355(a)]; see also section 301(d) of the Act [21 U.S.C. § 331(d)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.